Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Blinklab Limited ( (AU:BB1) ) just unveiled an announcement.
BlinkLab Limited, a digital health company specialising in AI-driven, smartphone-based tools for autism diagnosis, is led by an experienced team in digital healthcare, computer vision and brain science, supported by a Scientific Advisory Board of autism and neurodevelopment experts. The company’s flagship product, BlinkLab Dx1, is designed as a diagnostic aid for clinicians, capturing objective reflex data to improve the speed and accuracy of autism identification in children.
BlinkLab has notified investors that 37,913,846 fully paid ordinary shares will be released from escrow on 4 April 2026, alongside 3,000,000 performance rights and 35,000,000 options. The company plans to seek quotation of the newly released ordinary shares on the ASX, a move that will expand the pool of tradeable stock and could increase liquidity for existing and incoming shareholders as the business advances its autism diagnostics platform.
More about Blinklab Limited
BlinkLab Limited is a digital healthcare company founded by neuroscientists at Princeton University, focused on developing a smartphone-based diagnostic platform for autism. Its lead product, BlinkLab Dx1, uses smartphones, artificial intelligence and machine learning to provide clinicians with objective, reflex-based measures that support earlier and more accurate autism diagnosis, aiming to enable timely intervention during critical periods of brain development.
Average Trading Volume: 213,613
Technical Sentiment Signal: Buy
Current Market Cap: A$96.32M
Find detailed analytics on BB1 stock on TipRanks’ Stock Analysis page.